Incyte Paid $96 Million In Tax On A $689 Million Pretax Loss After Vega Charge Earned No Deduction
The $1.23 billion Vega write-off was not deductible, leaving Incyte with a $784.8 million third-quarter net loss despite 14% revenue growth.
Incyte, the biopharmaceutical company behind the blood-cancer drug Jakafi, booked a $95.955 million tax provision on a $688.8 million pretax loss in the third quarter, an effective tax rate of (13.9)%, according to its 10-Q filed Thursday. The reason is the $1.23 billion Vega Therapeutics research charge, which the company calls a one-time non-deductible item and which produced a $784.8 million net loss.
A charge the tax code ignores
Incyte said the unfavorable rate stems mainly from the "one-time non-deductible charge of $1.23 billion" tied to Vega, plus a net increase in valuation allowances against certain U.S. federal and state deferred tax assets. Tax credits, stock-compensation deductions and foreign tax effects partly offset both.
The comparison is stark. The prior quarter's filing showed a 22.1% rate on $751.5 million of pretax income, and a year earlier the third-quarter rate was 12.1% on $482.3 million. The loss was $3.86 per share, against net income of $424.2 million a year earlier.
For the first nine months, the rate was 74.4% on $406.3 million of pretax income, with net income of $104.1 million, down from $987.4 million.
Why Vega hit the income statement
Incyte bought Vega, a developer of antibody therapies for von Willebrand disease, for $1.25 billion in cash, completing the deal on July 6. It added $16.7 million of transaction costs, for $1.267 billion in total consideration.
The company treated the deal as an asset acquisition, because the lead drug, latarcibart, represents substantially all the value acquired. Of the total, $1.232 billion went to that in-process research asset, which has no alternative use, so Incyte expensed all of it as research and development. The other $35.3 million went to net assets, including a $37.5 million deferred tax asset.
Seller Star Therapeutics can receive up to $750 million more on U.S. net sales milestones. Nothing was recorded for that as of September 30.
The underlying business grew
Revenue rose 14% to $1.56 billion. Jakafi sales were $827 million, up 4%, and Opzelura cream sales were $255 million, up 36%. Incyte raised full-year 2026 guidance for total net sales to $5,210–$5,300 million.
The tax line has a balance-sheet side. Deferred income tax assets fell to $281.7 million at September 30 from $515.3 million at December 31, 2025. Cash taxes paid for nine months were $18.3 million, against $185.2 million a year earlier. The filing says the 2025 law change on expensing domestic research costs materially cut U.S. tax liabilities in 2025 and 2026.
Operating cash flow for the nine months was $201.7 million, against $870.2 million, which the company attributes mainly to the cash paid for Vega. Cash and marketable securities stood at $3.9 billion, with no borrowings on a $500 million credit facility.
Incyte's market value was $23.7 billion at Thursday's close, as it prepares fourth-quarter data readouts for povorcitinib in prurigo nodularis and ruxolitinib cream in hidradenitis suppurativa.
Sources
- 10-Q Filing — Incyte Corp. (INCY) — SEC EDGAR
- 10-Q Filing — Incyte Corp. (INCY), Q2 FY2026 filed 2026-07-28 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, incy-q32026xexx991.htm) — Incyte Corp., filed 2026-10-29 — SEC EDGAR
- Incyte Non-GAAP EPS of -$3.60 beats by $0.27, revenue of $1.56B beats by $100M (NASDAQ:INCY) | Seeking Alpha — seekingalpha.com
- Incyte: Q3 Earnings Snapshot – WTOP News — wtop.com
- Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates — Yahoo Finance
- Incyte: Q3 Earnings Snapshot | 9news.com — Associated Press
- Incyte: Q3 Earnings Snapshot | wusa9.com — Associated Press